AstraZeneca to outsource all manufacturing within next decade: report

Share this article:

AstraZeneca said it plans to outsource all of its drug manufacturing within the next 10 years, The Times of London reports.

“Manufacturing for AstraZeneca is not a core activity,” said David Smith, AstraZeneca's EVP of operations, in a report on the newspaper's Web site.

“AstraZeneca is about innovation and brand building … There are lots of people and organizations that can manufacture better than we can,” Smith added.

Smith is reportedly leading a restructuring at the company aimed at cutting costs and improving profitability.

He told The Times that the company's priority would be to outsource all of its manufacturing of active pharmaceutical ingredients.

This year to date, the Anglo-Swedish drugmaker has announced plans to phase out 7,600 staff, nearly 12% of its workforce, to help save the company an estimated $900 million by 2010.

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.